These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29581794)

  • 1. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.
    Verduin M; Compter I; Steijvers D; Postma AA; Eekers DBP; Anten MM; Ackermans L; Ter Laan M; Leijenaar RTH; van de Weijer T; Tjan-Heijnen VCG; Hoeben A; Vooijs M
    Dis Markers; 2018; 2018():2908609. PubMed ID: 29581794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine.
    Sanchez I; Rahman R
    Curr Oncol Rep; 2024 Oct; 26(10):1213-1222. PubMed ID: 39009914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroimaging: diagnosis and response assessment in glioblastoma.
    Clarke JL; Chang SM
    Cancer J; 2012; 18(1):26-31. PubMed ID: 22290254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
    de Godoy LL; Chawla S; Brem S; Mohan S
    Clin Cancer Res; 2023 Jul; 29(14):2588-2592. PubMed ID: 37227179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomics for precision medicine in glioblastoma.
    Aftab K; Aamir FB; Mallick S; Mubarak F; Pope WB; Mikkelsen T; Rock JP; Enam SA
    J Neurooncol; 2022 Jan; 156(2):217-231. PubMed ID: 35020109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiomics signature for temporal evolution and recurrence patterns of glioblastoma using multimodal magnetic resonance imaging.
    Chougule T; Gupta RK; Saini J; Agrawal S; Gupta M; Vakharia N; Singh A; Patir R; Vaishya S; Ingalhalikar M
    NMR Biomed; 2022 Mar; 35(3):e4647. PubMed ID: 34766380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New imaging techniques for more effective treatment in glioblastoma.
    Fay MF; Martin JH; Rose S
    Intern Med J; 2014 Jan; 44(1):5-6. PubMed ID: 24450518
    [No Abstract]   [Full Text] [Related]  

  • 10. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
    Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
    Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions.
    Chow D; Chang P; Weinberg BD; Bota DA; Grinband J; Filippi CG
    AJR Am J Roentgenol; 2018 Jan; 210(1):30-38. PubMed ID: 28981352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeted therapy in glioblastoma: update and perspectives].
    Idbaih A; Duran-Peña A; Alentorn A
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
    Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
    Front Immunol; 2021; 12():790674. PubMed ID: 34899760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging.
    Soni VS; Yanagihara TK
    Cancer Imaging; 2019 Nov; 19(1):76. PubMed ID: 31783910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?
    Boonzaier NR; Piccirillo SG; Watts C; Price SJ
    CNS Oncol; 2015; 4(6):399-410. PubMed ID: 26497327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Glioblastoma, Present and Future.
    Oberheim Bush NA; Hervey-Jumper SL; Berger MS
    World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma.
    Šamec N; Zottel A; Videtič Paska A; Jovčevska I
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding and Treating Glioblastoma.
    Wick W; Platten M
    Neurol Clin; 2018 Aug; 36(3):485-499. PubMed ID: 30072067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation.
    Katsila T; Matsoukas MT; Patrinos GP; Kardamakis D
    OMICS; 2017 Aug; 21(8):429-439. PubMed ID: 28816643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optic nerve glioblastoma detected by
    Rizzo V; Mattoli MV; Trevisi G; Coli A; Calcagni ML; Montano N
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):259-260. PubMed ID: 28802548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.